SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Research context
SymBio Pharmaceuticals Limited appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
SymBio Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 92.4% above its 200 day moving average.
From a valuation standpoint, the stock is 78.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.1.
SymBio Pharmaceuticals Limited's total revenue sank by 21.1% to $654M since the same quarter in the previous year.
Its net income has dropped by 89.7% to $-1B since the same quarter in the previous year.
Based on the above factors, SymBio Pharmaceuticals Limited gets an overall score of 2/5.